Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways.

Pang X, Yi T, Yi Z, Cho SG, Qu W, Pinkaew D, Fujise K, Liu M.

Cancer Res. 2009 Jan 15;69(2):518-25. doi: 10.1158/0008-5472.CAN-08-2531.

2.
3.

Inhibitors of vascular endothelial growth factor in cancer.

Pourgholami MH, Morris DL.

Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):343-7. Review.

PMID:
18855647
4.

Hypoxia signalling through mTOR and the unfolded protein response in cancer.

Wouters BG, Koritzinsky M.

Nat Rev Cancer. 2008 Nov;8(11):851-64. doi: 10.1038/nrc2501. Epub 2008 Oct 10. Review.

PMID:
18846101
5.

[Basic science of angiogenesis and its progress in clinical application].

Takakura N.

Rinsho Ketsueki. 2008 Oct;49(10):1451-9. Review. Japanese. No abstract available.

PMID:
18833929
6.

Endothelial p70 S6 kinase 1 in regulating tumor angiogenesis.

Liu LZ, Zheng JZ, Wang XR, Jiang BH.

Cancer Res. 2008 Oct 1;68(19):8183-8. doi: 10.1158/0008-5472.CAN-08-0819.

7.

Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma.

Li W, Tan D, Zhang Z, Liang JJ, Brown RE.

Oncol Rep. 2008 Oct;20(4):713-9.

PMID:
18813808
8.

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.

Roodhart JM, Langenberg MH, Witteveen E, Voest EE.

Curr Clin Pharmacol. 2008 May;3(2):132-43. Review.

PMID:
18690886
9.

Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.

Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R.

Clin Cancer Res. 2008 Jun 1;14(11):3589-97. doi: 10.1158/1078-0432.CCR-07-4306.

10.

Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling.

Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB, Liu M.

Cancer Res. 2008 Mar 15;68(6):1843-50. doi: 10.1158/0008-5472.CAN-07-5944. Erratum in: Cancer Res. 2008 May 15;68(10):4012.

11.

Acetyl-keto-beta-boswellic acid induces apoptosis through a death receptor 5-mediated pathway in prostate cancer cells.

Lu M, Xia L, Hua H, Jing Y.

Cancer Res. 2008 Feb 15;68(4):1180-6. doi: 10.1158/0008-5472.CAN-07-2978.

12.

Capsiate, a nonpungent capsaicin-like compound, inhibits angiogenesis and vascular permeability via a direct inhibition of Src kinase activity.

Pyun BJ, Choi S, Lee Y, Kim TW, Min JK, Kim Y, Kim BD, Kim JH, Kim TY, Kim YM, Kwon YG.

Cancer Res. 2008 Jan 1;68(1):227-35. doi: 10.1158/0008-5472.CAN-07-2799.

13.

Molecular design and clinical development of VEGFR kinase inhibitors.

Zhong H, Bowen JP.

Curr Top Med Chem. 2007;7(14):1379-93. Review.

PMID:
17692027
14.

Tumour-derived fibroblast growth factor-2 exerts lymphangiogenic effects through Akt/mTOR/p70S6kinase pathway in rat lymphatic endothelial cells.

Matsuo M, Yamada S, Koizumi K, Sakurai H, Saiki I.

Eur J Cancer. 2007 Jul;43(11):1748-54. Epub 2007 Jun 13.

PMID:
17570654
15.

Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review).

Kanda S, Miyata Y, Kanetake H, Smithgall TE.

Int J Mol Med. 2007 Jul;20(1):113-21. Review.

PMID:
17549397
16.

Effect of acetyl 11-keto beta-boswellic acid on metastatic growth factor responsible for angiogenesis.

Singh SK, Bhusari S, Singh R, Saxena A, Mondhe D, Qazi GN.

Vascul Pharmacol. 2007 May;46(5):333-7. Epub 2006 Nov 10.

PMID:
17257903
17.

Boswellic acids: biological actions and molecular targets.

Poeckel D, Werz O.

Curr Med Chem. 2006;13(28):3359-69. Review.

PMID:
17168710
18.

Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis.

Shibuya M.

J Biochem Mol Biol. 2006 Sep 30;39(5):469-78. Review.

PMID:
17002866
19.

Vascular endothelial growth factor signaling pathways: therapeutic perspective.

Kowanetz M, Ferrara N.

Clin Cancer Res. 2006 Sep 1;12(17):5018-22. Review.

20.

Integrin-regulated FAK-Src signaling in normal and cancer cells.

Mitra SK, Schlaepfer DD.

Curr Opin Cell Biol. 2006 Oct;18(5):516-23. Epub 2006 Aug 17. Review.

PMID:
16919435

Supplemental Content

Support Center